巴塞罗那B期肝癌治疗现状及进展

摘要/Abstract

摘要：

原发性肝癌（primary carcinoma of liver,PL）是恶性程度最高的肿瘤之一,对于不同分期的患者需要选择最合适的治疗手段,以达到最佳的治疗效果。目前国际上有多个肝癌分期标准,其中应用最广泛的是巴塞罗那（Barcelona clinic liver cancer,BCLC）分期。对BCLC/B期患者,BCLC分期推荐的治疗只有动脉化疗栓塞（Transarterial chemoembolization,TACE）。而BCLC/B期异质性较大,对于部分患者,手术切除、射频消融、药物治疗均显示出优于TACE的疗效。联合治疗在BCLC/B期中也显示出治疗优势,但需要更高级别的临床研究证实。本文主要叙述BCLC/B期患者治疗现状及进展。

贺国盛, 黎功. 巴塞罗那B期肝癌治疗现状及进展[J]. 肝癌电子杂志, 2019, 6(4): 9-13.

图/表 4

参考文献 36

[1]	Bray F, Ferlay J, Soerjomataram I , et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: A Cancer Journal for Clinicians, 2018,68(6):394-424.
[2]	Sobin LH, Compton CC . TNM seventh edition: what's new, what's changed: communication from the International Union Against Cancer and the American Joint Committee on Cancer[J]. Cancer, 2010,116(22):5336-5339.
[3]	Okuda K, Ohtsuki T, Obata H , et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients[J]. Cancer, 1985,56(4):918-928.
[4]	Kudo M, Chung H, Haji S , et al. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score[J]. Hepatology, 2004,40(6):1396-1405.
[5]	Llovet JM, Bru C, Bruix J . Prognosis of hepatocellular carcinoma: the BCLC staging classification[J]. Semin Liver Dis, 1999,19(3):329-338.
[6]	Yau T, Tang VY, Yao T , et al. Development of Hong Kong Liver Cancer Staging System With Treatment Stratification for Patients With Hepatocellular Carcinoma[J]. Gastroenterology, 2014,146(7):1691-1700.
[7]	Llovet JM, Bruix J . Prospective validation of the Cancer of the Liver Italian Program (CLIP) score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma[J]. Hepatology, 2000,32:679-680.
[8]	Forner A, Reig M, Bruix J . Hepatocellular carcinoma[J]. Lancet, 2018,391(10127):1301-1314.
[9]	European Association for the Study of the Liver. European Association for the Study of the Liver, EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018,69:182-236.
[10]	Llovet JM, Burroughs A, Bruix J . Hepatocellular carcinoma[J]. Lancet, 2003,362(9399):1907-1917.
[11]	Yau T, Tang VY, Yao T , et al. Development of Hong Kong Liver Cancer Staging System with treatment stratification for patients with hepatocellular carcinoma[J]. Gastroenterology, 2014,146(7):1691-1700.
[12]	Jung YK, Jung CH, Seo YS , et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A[J]. J Gastroenterol Hepatol, 2016,31(2):467-474.
[13]	European Association For The Study Of The Liver. European Organisation For Research And Treatment Of Cancer, EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012,56:908-943.
[14]	Lee S, Kim BK, Song K , et al. Subclassification of Barcelona Clinic Liver Cancer B and C hepatocellular carcinoma: a cohort study of the multicenter registry database[J]. J Gastroenterol Hepatol, 2016,31(4):842-847.
[15]	Bolondi L, Burroughs A, Dufour J , et al. Heterogeneity of patients with intermediate (BCLC B) hepatocellular carcinoma: proposal for a subclassification to facilitate treatment decisions[J]. Seminars in Liver Disease, 2013,32(04):348-359.
[16]	Mazzaferro V, Llovet JM, Miceli R , et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis[J]. Lancet Oncol, 2009,10(1):35-43.
[17]	Kudo M, Arizumi T, Ueshima K , et al. Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified Bolondi's Subclassification (Kinki Criteria)[J]. Digestive Diseases, 2015,33(6):751-758.
[18]	Villanueva A . Hepatocellular Carcinoma[J]. N Engl J Med, 2019,380(15):1450-1462.
[19]	Lencioni R, de Baere T, Soulen MC , et al. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data[J]. Hepatology, 2016,64(1):106-116.
[20]	Oliveri RS, Wetterslev J, Gluud C . Transarterial (chemo) embolisation for unresectable hepatocellular carcinoma (Review)[J]. Cochrane Database of Systematic Reviews, 2011(3):1-59.
[21]	Vitale A, Cucchetti A, Qiao GL , et al. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit[J]. J Hepatol, 2014,60(6):1165-1171.
[22]	Jung YK, Jung CH, Seo YS , et al. BCLC stage B is a better designation for single large hepatocellular carcinoma than BCLC stage A[J]. J Gastroenterol Hepatol, 2016,31(2):467-474.
[23]	Wang YY, Zhong JH, Xu HF , et al. A modified staging of early and intermediate hepatocellular carcinoma based on single tumour > 7 cm and multiple tumours beyond up-to-seven criteria[J]. Aliment Pharmacol Ther, 2019,49(2):202-210.
[24]	Guo Z, Zhong J, Jiang J , et al. Comparison of survival of patients with BCLC stage A hepatocellular carcinoma after hepatic resection or transarterial chemoembolization: a propensity score-based analysis[J]. Ann Surg Oncol, 2014,21(9):3069-3076.
[25]	Luo J, Peng ZW, Guo RP , et al. Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis[J]. Radiology, 2011,259(1):286-295.
[26]	Di Sandro S, Centonze L, Pinotti E , et al. Surgical and oncological outcomes of hepatic resection for BCLC-B hepatocellular carcinoma: a retrospective multicenter analysis among 474 consecutive cases[J]. Updates in Surgery, 2019,71(2):285-293.
[27]	Yin L, Li H, Li AJ , et al. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan Criteria: a RCT[J]. J Hepatol, 2014,61(1):82-88.
[28]	Kim H, Ahn SW, Hong SK , et al. Survival benefit of liver resection for Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma[J]. Br J Surg, 2017,104(8):1045-1052.
[29]	Peng Y, Liu F, Xu H , et al. Is laparoscopic liver resection suitable for selected patients with BCLC stage B HCC? A propensity score-matched analysis[J]. HPB, 2019,8(104):1045-1052 .
[30]	Tsilimigras DI, Bagante F, Sahara K , et al. Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) Stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification[J]. Ann Surg Oncol, 2019,26(11):3693-3700.
[31]	Yang B, Zheng B, Yang M , et al. Liver resection versus transarterial chemoembolization for the initial treatment of Barcelona Clinic Liver Cancer stage B hepatocellular carcinoma[J]. Hepatol Int, 2018,12(5):417-428.
[32]	Galle PR, Tovoli F, Foerster F , et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy[J]. J Hepatol, 2017,67(1):173-183.
[33]	Bruix J, Raoul J, Sherman M , et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial[J]. J Hepatol, 2012,57(4):821-829.
[34]	Kudo M, Finn RS, Qin S , et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018,391(10126):1163-1173.
[35]	Kudo M, Ueshima K, Chan S , et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond Up-To-Seven criteria and Child-Pugh A liver function: a proof-of-concept study[J]. Cancers, 2019,11(8):1084.
[36]	Ho EY, Cozen ML, Shen H , et al. Expanded use of aggressive therapies improves survival in early and intermediate hepatocellular carcinoma[J]. HPB, 2014,16(8):758-767.

巴塞罗那B期肝癌治疗现状及进展

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 36

相关文章 1

编辑推荐

Metrics

本文评价